Viridian Therapeutics, Inc.\de
A biotechnology company developing new treatments for thyroid eye disease, a rare autoimmune condition that makes the tissues behind the eye swell and bulge. Its lead experimental medicine, veligrotug, is an antibody designed to block the protein driving that swelling. The company was formed under its current name in 2022, taking "Viridian" from the green pigment, a nod to fresh growth.
Granted 14.1K · Bought 3.23M
Bought 545.5K
Bought 476.7K
Sold 37.0K
Bought 1.81M
Bought 200.0K
Granted 945.5K · Bought 14.0K
Granted 50.0K · Sold 250.0K
Granted 285.3K
Granted 118.3K
Granted 250.0K · Bought 9.5K
Granted 192.0K
Granted 43.9K
Bought 21.4K
Granted 59.5K · Sold 89.5K
Bought 5.0K
Bought 9.3K
Granted 778 · Bought 10.0K · Sold 12.0K
Granted 10.5K
Granted 11.7K
Granted 11.7K
Sold 2.3K
Granted 89.0K · Sold 89.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC +2 co-filersDirector, 10% owner · 5 transactions | — | 9.01M | 14.1K | 3.23M | — |
| Booth BruceDirector · 1 transaction | — | 8.44Mas of Feb 2018 | — | 545.5K | — |
| Logos Global Master Fund LP10% owner · 3 transactions | — | 6.00Mas of Nov 2020 | — | 476.7K | — |
| Lefkoff KyleDirector · 10 transactions | — | 4.18Mas of Mar 2017 | — | — | 37.0K |
| Fairmount Funds Management LLC +4 co-filersDirector, 10% owner, Director · 7 transactions | — | 1.85Mas of Mar 2024 | — | 1.81M | — |
| FHMLSP, L.L.C. +2 co-filers10% owner · 1 transaction | — | 1.51Mas of Sep 2021 | — | 200.0K | — |
| Riccitelli Samuel DPresident & CEO, Director · 12 transactions | — | 674.5Kas of Oct 2016 | 945.5K | 14.0K | — |
| Violin JonathanChief Executive Officer, Director · 14 transactions | — | 430.9Kas of Feb 2023 | 50.0K | — | 250.0K |
| Lebow Bennett SDirector, 10% owner · 3 transactions | — | 429.4Kas of Feb 2017 | 285.3K | — | — |
| Marshall William StuartPresident & CEO, Director · 3 transactions | — | 273.1Kas of Aug 2020 | 118.3K | — | — |
| Myers Scott DunsethChief Executive Officer, Director · 3 transactions | — | 259.5Kas of Apr 2023 | 250.0K | 9.5K | — |
| Seymour Tamara ACFO, Secretary, Treasurer · 8 transactions | — | 106.4Kas of Oct 2016 | 192.0K | — | — |
| Leverone Jason A.CFO, Treasurer & Secretary · 3 transactions | — | 48.8Kas of Mar 2020 | 43.9K | — | — |
| Mahoney Stephen F.President and CEO, Director · 2 transactions | — | 33.3K | — | 21.4K | — |
| Meisner LaraChief Legal Officer · 28 transactions | — | 30.0Kas of Jun 2023 | 59.5K | — | 89.5K |
| Beetham Thomas W.Chief Operating Officer · 2 transactions | — | 13.4K | — | 5.0K | — |
| Levy Adam ScottChief Business Officer · 2 transactions | — | 13.0Kas of Aug 2018 | — | 9.3K | — |
| Hughes Thomas E.Director · 3 transactions | — | 12.8Kas of Oct 2018 | 778 | 10.0K | 12.0K |
| Schuling Douglas ADirector · 3 transactions | — | 5.5Kas of Aug 2015 | 10.5K | — | — |
| Smith Robin LDirector · 4 transactions | — | 1.9Kas of Feb 2017 | 11.7K | — | — |
| Gonyer David ADirector · 4 transactions | — | 1.9Kas of Feb 2017 | 11.7K | — | — |
| Harmon SethChief Financial Officer · 1 transaction | — | 1.7K | — | — | — |
| Tousignant JenniferChief Legal Officer · 2 transactions | — | 610 | — | — | 2.3K |
| Katz BarrettChief Medical Officer · 8 transactions | — | 0as of Jan 2023 | 89.0K | — | 89.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +5.85M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.